Self-regulation of autologous cell therapies

Bernard E Tuch and Dominic M Wall
Med J Aust 2014; 200 (4): . || doi: 10.5694/mja13.11043
Published online: 3 March 2014

A first step for a virtually unregulated industry

  • Bernard E Tuch1,2
  • Dominic M Wall3,4

  • 1 NSW Stem Cell Network, Sydney, NSW.
  • 2 Centre for Genetic Diseases, Monash Institute of Medical Research, Monash University, Melbourne, VIC.
  • 3 Australia and New Zealand Region, International Society for Cellular Therapy, Melbourne, VIC.
  • 4 Department Pathology, University of Melbourne, Melbourne, VIC.


We thank Insoo Hyun for critical reading of the manuscript, Deborah Monk for advice about the code of conduct of Medicines Australia, and Heather Main for input into the steering committee and its operation.

Competing interests:

Bernard Tuch is a non-executive director of Living Cell Technologies Ltd, which is conducting clinical trials with xenografted cell therapies. He has received speaker and chairman fees from Abbott Laboratories and Merck Sharp and Dohme. Dominic Wall holds an unpaid management position for Cell Therapies Pty Ltd.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.